Form 4: Sutro Biopharma Director Daniel H. Petree Acquires 35,000 Stock Options

Director Daniel H. Petree acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.

Summary

• On June 6, 2024, Daniel H. Petree, a director of Sutro Biopharma, Inc., acquired 35,000 stock options.
• The exercise price of these options is $3.76.
• The options vest monthly starting July 6, 2024, with full vesting by the earlier of the 2025 annual stockholders meeting or June 6, 2025.
• The options expire on June 6, 2034.
• Following the transaction, Petree directly owns 35,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it simply reports a transaction. The grant of options is generally a positive sign, but it's a routine event.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service by the reporting person to the issuer.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the compensation and equity ownership of company directors.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align the interests of management with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
• Comparable companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.
• Employees may view the option grant as a positive sign of company stability and growth potential.

Key Dates